



"Public Health Perspectives on Dysmenorrhoea: Management, Contributing Factors, and Preventive Strategies"

Alhaji saleh Isyaku, Aisha Ibrahim Dakingari

¹. Department of Epidemiology and Evidence based Medicine, First Moscow State Medical University, I.M Sechenov, Russia.

¹. Faculty of Pharmacy, Kalinga University, Naya Raipur, Chhattisgarh India.

Abstract

Dysmenorrhoea is a condition marked by intense uterine pain during menstruation, often presenting as cyclic lower abdominal discomfort. It is typically classified into two categories: primary dysmenorrhea, which occurs without any underlying pathology, and secondary dysmenorrhea, which is linked to an identifiable medical condition. It is estimated that 40–70% of women of reproductive age experience dysmenorrhea, along with its accompanying psychological, physical, and social challenges. While the exact mechanisms behind dysmenorrhea are not fully understood, it is believed to result from excessive prostaglandin production leading to increased uterine muscle activity and reduced blood flow, causing pain akin to uterine angina. A thorough medical history is essential for diagnosing dysmenorrhea and distinguishing between its primary and secondary forms. Treatment typically focuses on symptom relief, with more invasive procedures reserved for cases involving secondary causes or those that do not respond to initial treatments. Primary dysmenorrhea is often managed with reassurance and simple pain relievers, while secondary dysmenorrhea requires further investigation and targeted treatment of the underlying condition. This article provides an overview of the management strategies for dysmenorrhea.

Keywords: Dysmenorrhea, Uterine, Abdominal, Pathology, Prostaglandin.

Received 01 June., 2025; Revised 06 June., 2025; Accepted 08 June., 2025 © The author(s) 2025.

Published with open access at www.questjournals.org

I. Introduction

Dysmenorrhea, or menstrual pain, is a prevalent condition that affects a large proportion of women globally, especially during adolescence and early adulthood. It is typically classified into two types: primary dysmenorrhea, where there is no underlying medical condition, and secondary dysmenorrhea, which is linked to specific gynecological issues. The condition not only causes physical discomfort but also has broader effects on mental health, social interactions, and economic productivity due to its impact on daily functioning. Despite the availability of effective treatments, dysmenorrhea often remains untreated, particularly among adolescents, highlighting its significance as a public health concern.

From a broader health perspective, dysmenorrhea has far-reaching implications, affecting healthcare utilization, workplace productivity, and overall quality of life. Contributing factors include hormonal imbalances, genetic susceptibility, and lifestyle choices such as diet and physical activity. Although it is not usually classified as a chronic pain condition, dysmenorrhea shares similarities with other chronic pain disorders like irritable bowel syndrome (IBS) and fibromyalgia, as they often lack identifiable organ pathology. Moreover, it is frequently a comorbid condition in women with chronic pelvic pain (CPP).[1,2,3,4]

Emerging research suggests that alterations in the body's response to pain, including changes in how the brain processes pain signals and the function of the hypothalamic–pituitary–adrenal (HPA) axis, may play a role in dysmenorrhea. Studies have shown that reduced cortisol levels, or a diminished cortisol response, are present in several chronic pain conditions, including IBS, fibromyalgia, and CPP. However, it is unclear whether repeated episodes of menstrual pain can trigger changes in the HPA axis or if these hormonal changes increase

susceptibility to chronic pain. Understanding these mechanisms is key to developing more effective management strategies for dysmenorrhea and reducing its impact on women's health and wellbeing.

Psychophysical research has shown heightened responses to both somatic and visceral stimuli in women with dysmenorrhea compared to those without pain, suggesting alterations within the pain processing pathways. This study had two main objectives: (1) to confirm previous findings of increased pain sensitivity in women with dysmenorrhea, and (2) to investigate whether this condition is linked to other characteristics typical of chronic pain disorders, such as psychological changes, decreased quality of life (QoL), impaired hypothalamic-pituitary-adrenal (HPA) axis function, and altered central pain processing. If dysmenorrhea shares similarities with other chronic pain conditions, repeated monthly painful episodes might be expected to result in changes in central pain processing, along with a decrease in QoL and HPA axis functionality. The study utilized both behavioral assessments and functional magnetic resonance imaging (fMRI) to examine responses to experimental pain stimuli in otherwise healthy women, with and without dysmenorrhea, throughout the menstrual cycle. This approach enabled control for hormonal variations and provided an opportunity to compare the groups during periods of differing background pain levels, as well as when no significant difference in pain was present.[5,6,7].

2.1 Understanding dysmenorrhoea

Dysmenorrhoea refers to the medical condition of painful menstrual periods resulting from uterine contractions. It is a common gynecological issue that can greatly impact a woman's quality of life. Dysmenorrhoea is typically divided into two categories: 1)primary dysmenorrhoea and 2)secondary dysmenorrhoea.[8,9]

2.2 Primary Dysmenorrhoea

Definition: Menstrual pain that occurs without any underlying pelvic disorder, commonly emerging a few months to a year after the onset of menstruation (menarche), particularly in adolescents and young women.

Cause: Primary dysmenorrhea is linked to the excessive production of prostaglandins, which cause the uterus to contract more intensely. These contractions decrease blood flow to the uterine lining, resulting in pain.

Symptoms:

- a. Cramping pain in the lower abdomen, which typically begins a day or two before menstruation or coincides with menstrual bleeding.
- b. The pain may radiate to the lower back or thighs.
- c. Additional symptoms may include nausea, diarrhea, headaches, and fatigue.

Management:

- a. Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are effective in reducing prostaglandin levels.
- b. Hormonal contraceptives (e.g., birth control pills) help regulate or suppress ovulation, reducing prostaglandin production.
- c. Lifestyle interventions such as regular physical activity, relaxation techniques, and heat therapy applied to the abdomen can also be helpful.

2.3 Secondary Dysmenorrhoea

Definition: Menstrual pain caused by an underlying pelvic condition such as endometriosis, uterine fibroids, or pelvic inflammatory disease (PID). This type of dysmenorrhea often appears later in life, usually after the age of 25.

Cause: Pain in secondary dysmenorrhea is associated with structural abnormalities or diseases affecting the uterus or pelvic organs.

Symptoms:

- a. Pain may start earlier in the menstrual cycle and last longer than in primary dysmenorrhea
- b. The pain tends to be more severe and may be accompanied by heavy or irregular bleeding.
- c. Other symptoms, such as painful intercourse or pelvic discomfort between periods, may also occur.

Management:

- a. Treatment focuses on managing the underlying condition (e.g., hormonal treatments or surgical interventions for fibroids or endometriosis).
- b. Pain relief options include NSAIDs and hormonal therapies.
- c. In some cases, surgical procedures like laparoscopy may be necessary to diagnose or treat the cause.

Key Differences between Primary and Secondary Dysmenorrhea:

Primary and secondary dysmenorrhea are two types of menstrual cramps but differ in their causes and symptoms:

a. Primary Physical Diseases

Causes: It is associated with the menstrual cycle itself, primarily due to the release of prostaglandins, which cause uterine contractions.

Onset: Often starting within a few years of menarche (first menstrual period), it mainly affects adolescents and young adults

Symptoms: The pain is usually painful, starts before menstruation or at the beginning of menstruation, lasts 1-3 days.

Associated conditions: Usually, there is no association with cervical cancer.

Management: It is often managed with NSAIDs, hormonal contraceptives, or lifestyle changes.

b. Secondary dysmenorrhea

Causes: It develops due to pelvic conditions, such as endometriosis, adenomyosis, fibroids, or pelvic inflammatory disease (PID).

Onset: It can begin late in life, usually after 25-30 years, and can worsen over time.

Symptoms: Pain may last longer than initial dysmenorrhea, often starting before menstruation and continuing throughout the cycle; it can be severe and persistent.

Associated Conditions: There is a recognized condition of the knee, which requires specific treatment.

Management: Treatment is often focused on treating the cause, sometimes requiring surgery or other therapy.

In short, primary dysmenorrhea is painful without any noticeable symptoms, while secondary dysmenorrhea involves menstrual pain which is a recognized condition.

3.1 Diagnosis of Dysmenorrhea

Medical History: The physician will ask about menstrual patterns, pain characteristics, and any other related symptoms.

Physical Examination: A pelvic exam may be conducted to check for abnormalities.

Imaging: For suspected secondary dysmenorrhoea, tests like ultrasound or MRI can help identify conditions such as fibroids or endometriosis.

Laparoscopy: In certain cases, laparoscopy, is a minor surgical procedure, may be used to directly visualize and diagnose conditions like endometriosis.

4.1 Treatment Approaches

Medications: NSAIDs and hormonal therapies are commonly prescribed.

Lifestyle Adjustments: Regular exercise, yoga, dietary changes, and stress management test can be beneficial in managing symptoms.

Surgical Interventions: In severe cases of secondary dysmenorrhoea, surgery may be required to remove fibroids, treat endometriosis, or address other structural abnormalities[10,11,12].

Prognosis

Primary Dysmenorrhoea: Often improves with age or following childbirth and can usually be well-managed with medications and lifestyle adjustments.

Secondary Dysmenorrhoea: Prognosis depends on the underlying cause, with effective treatment often leading to pain relief, though it may require more advanced interventions.

Accurate diagnosis of the type of dysmenorrhoea is essential for determining the appropriate treatment plan. Women who experience severe or persistent menstrual pain should seek medical evaluation to identify the cause and receive tailored treatment for their condition.[13,14,15,16,17]

4.1 Contributing factors to dysmenorrhoea

Several elements contribute to the onset and intensity of dysmenorrhoea, encompassing both biological and lifestyle factors. These influences can worsen menstrual discomfort, especially in cases of primary dysmenorrhoea, and may also play a role in secondary dysmenorrhoea when associated with underlying health conditions. The key contributing factors include[18,19,20]:

4.1.1 Hormonal Fluctuations

Prostaglandins: Elevated levels of prostaglandins, which are hormone-like compounds, are a primary cause of uterine contractions during menstruation. An excess of these chemicals can lead to stronger, more frequent contractions, increasing the severity of menstrual pain.

Estrogen and Progesterone: Imbalances in these key reproductive hormones can also affect the intensity of menstrual pain by altering uterine muscle contractions and inflammation.

4.1.2 Genetic Factors

A hereditary predisposition to dysmenorrhoea increases the likelihood of experiencing painful menstruation. Women whose close female relatives suffer from severe menstrual pain are more prone to developing the condition themselves.

4.1.3 Lifestyle Influences

Dietary Habits: Consuming a diet low in fresh fruits, vegetables, and essential fatty acids, while high in caffeine, salt, and processed foods, can exacerbate menstrual discomfort. Deficiencies in nutrients like magnesium and omega-3 fatty acids, which help reduce inflammation, have been associated with more intense dysmenorrhoea.

Lack of Physical Activity: A sedentary lifestyle can contribute to increased menstrual pain, whereas regular exercise helps reduce cramping by improving circulation and decreasing stress levels.

Smoking and Alcohol Use: Both smoking and excessive alcohol consumption are linked to heightened menstrual pain. Smoking reduces oxygen flow to pelvic tissues, while alcohol can contribute to increased inflammation.

4.1.4 Psychological Stress

Emotional stress and anxiety can intensify the perception of pain and worsen dysmenorrhoea symptoms. Prolonged stress may also disrupt hormonal balance, making menstrual pain more severe.

4.1. 5. Obesity

A higher body mass index (BMI) is correlated with more severe dysmenorrhoea. Excess weight can increase inflammation and lead to hormonal imbalances, both of which may exacerbate menstrual pain.

4.1.6. Underlying Health Conditions (Secondary Dysmenorrhoea)

Endometriosis: A condition where tissue similar to the uterine lining grows outside the uterus, leading to chronic and severe menstrual pain.

Uterine Fibroids: Non-cancerous growths in the uterus that can cause intense pain and heavy bleeding during menstruation.

Pelvic Inflammatory Disease (PID): Infections in the reproductive organs can lead to inflammation and pain, particularly during menstruation.

Adenomyosis: This occurs when the uterine lining grows into the muscular wall of the uterus, causing intense cramps and heavy bleeding.

4.1. 7. Age and Menstrual History

Dysmenorrhoea is more prevalent in adolescents and young women, often beginning shortly after the onset of menstruation. It frequently improves with age or following childbirth as hormonal levels stabilize.

By addressing these contributing factors through changes in lifestyle, appropriate medical treatments, and effective stress management, the intensity of dysmenorrhoea can be alleviated, improving overall menstrual health.[20,21,22,23,24,25].

5.1 Management of dysmenorrhoea

Dysmenorrhea, or painful menstruation, can be categorized into two types: primary dysmenorrhea, which occurs without any underlying gynecological condition, and secondary dysmenorrhea, which is linked to conditions like endometriosis, fibroids, or pelvic inflammatory disease.[26,27].

5.2 Management of Primary Dysmenorrhea:

Non-Pharmacological Approaches:

Heat therapy: Applying heat to the lower abdomen, such as with a heating pad or hot water bottle, can help alleviate menstrual pain.

Exercise: Engaging in regular physical activity can enhance circulation and reduce menstrual discomfort.

Dietary adjustments: A diet that includes plenty of fruits, vegetables, and whole grains may help reduce symptoms. Limiting caffeine and salt intake can also minimize bloating and irritability.

Stress management: Practices such as yoga, meditation, and relaxation exercises may reduce symptom severity.[28,29,30].

Pharmacological Approaches:

NSAIDs (Nonsteroidal Anti-inflammatory Drugs): Medications like ibuprofen, naproxen, and mefenamic acid are effective in easing menstrual pain by blocking prostaglandin production.

Hormonal contraceptives: Options such as combined oral contraceptives, patches, or vaginal rings can help regulate or suppress menstruation, thereby reducing the intensity of dysmenorrhea.

Progestin-only methods: Progestin-only pills, injectables (e.g., Depo-Provera), or intrauterine systems like Mirena can reduce menstrual pain by thinning the lining of the uterus.

Other Medical Treatments:

Transcutaneous electrical nerve stimulation (TENS): This technique involves using low-voltage electrical currents to interfere with pain signals.

Acupuncture and acupressure: Some research suggests that these methods may help alleviate dysmenorrhea.

Magnesium and vitamin B1 supplements: Evidence indicates that these supplements may lower pain severity.

5.3 Management of Secondary Dysmenorrhea:

5.3.1. Treating underlying conditions: Conditions such as endometriosis, adenomyosis, or pelvic infections require appropriate management, often combining medical and surgical treatments.

5.3.2 Endometriosis: Treatments may include hormonal therapies such as GnRH agonists, oral contraceptives, or progestins, or surgery to remove endometrial tissue.

5.3.3 Fibroids: Medications like GnRH agonists or surgical procedures such as myomectomy may be necessary. Pelvic inflammatory disease: Antibiotics are essential for treating the infection.

5.3.4 Pain management: Alongside treating the underlying condition, NSAIDs and hormonal therapies can help alleviate the pain associated with secondary dysmenorrhea.

When to Seek Medical Advice:

If symptoms worsen or do not respond to standard treatments.

If dysmenorrhea begins after the age of 25, which may suggest secondary causes.

If additional symptoms are present, such as heavy menstrual bleeding, irregular periods, or pain that occurs outside of menstruation.[31,32,33].

5.4 Treatment Approach:

The goal of treatment for dysmenorrhea is to relieve symptoms, typically through the use of prostaglandin-inhibiting analgesics that target the physiological mechanisms of menstrual pain, while also addressing any underlying pathology. Many studies have used patient self-reports via visual analogue scales, quality of life assessments, or other tools like the Menstrual Distress or Menstrual Symptom Questionnaires.[34,35].

5.4.1 Prognosis:

Few long-term studies have investigated the progression and outcome of either primary or secondary dysmenorrhea. Primary dysmenorrhea often improves during a woman's third decade of life and tends to decrease after childbirth. The prognosis for secondary dysmenorrhea varies depending on the underlying condition, as the severity, progression, and outcome depend on the specific pathology involved.[35,36,37].

6.1 Preventive strategies in public health

Dysmenorrhea, characterized by painful menstrual periods, is a common issue affecting many women of reproductive age, often leading to significant discomfort and negatively impacting their quality of life. In public health, efforts to prevent dysmenorrhea include strategies for both primary prevention (lowering the incidence of dysmenorrhea) and secondary prevention (minimizing the severity and effects of the condition). Below are key strategies for prevention[38,39,40]:

6.1.1. Educational and Awareness Initiatives

Menstrual Health Education: Public health initiatives can raise awareness among young women about menstrual health, helping them recognize the signs of dysmenorrhea, understand the underlying causes, and adopt healthier behaviors.

Knowledge of Treatment Options: Providing information about non-medical approaches such as heat therapy, dietary adjustments, or exercise, along with medical treatments like NSAIDs or hormonal contraceptives, can assist women in managing their symptoms effectively.

6.1.2. Lifestyle Adjustments

Nutrition and Diet: Promoting a diet rich in omega-3 fatty acids, magnesium, and vitamin B1 may alleviate menstrual pain. Additionally, minimizing the intake of processed foods, caffeine, and alcohol can help prevent symptom exacerbation.

Physical Exercise: Engaging in regular physical activities such as aerobic exercise or yoga has been shown to help alleviate dysmenorrhea by enhancing blood circulation, reducing stress, and balancing hormone levels.

Stress Reduction: Practices like mindfulness, meditation, and relaxation techniques can help manage stress, which can otherwise worsen menstrual pain.

6.1.3. Healthcare Accessibility

Ensuring Access to Reproductive Health Services: It is essential for women to have access to a full range of reproductive health services, which includes regular check-ups and affordable treatment options for conditions like dysmenorrhea. Providing easy access to medications, such as NSAIDs and hormonal therapies, without unnecessary barriers plays a key role in effective health management.

Early Detection and Intervention: Identifying severe dysmenorrhea early or diagnosing underlying conditions such as endometriosis can lead to more effective treatment and better management of the symptoms.

6.1.4. Policy and Environmental Changes

Supportive Workplace and School Policies: Policies that provide menstrual products, flexible work or school schedules for those experiencing severe pain, and create an open dialogue about menstrual health can help reduce stigma and support women dealing with dysmenorrhea.

Advocating for Research and Policy: Encouraging research into dysmenorrhea's causes and treatments and advocating for policies that include menstrual health as part of broader public health efforts can lead to improved outcomes.

6.1.5. Community Support

Peer and Community Support: Initiatives that create peer support groups or community-based programs offer a space for women to share their experiences and coping strategies. This not only helps in managing the condition but also fosters a sense of solidarity and reduces isolation.

When these strategies are integrated into a coordinated public health approach, they can help lower the incidence and impact of dysmenorrhea, ultimately enhancing the health and well-being of women.[41,42,43].

7.1 Policy implications

The policy considerations surrounding dysmenorrhea, or painful menstruation, go beyond individual health, influencing gender equity, access to healthcare, and employment rights. Tackling dysmenorrhea through policy changes can enhance women's quality of life and ensure equitable treatment in both social and professional environments. Key policy areas include:

7.1.1. Access to Healthcare and Insurance

Enhanced Treatment Access: Policymakers should ensure that treatments for dysmenorrhea, such as pain medications, hormonal therapies, and alternative options like acupuncture or physical therapy, are both affordable and widely accessible. Universal health coverage should incorporate dysmenorrhea management within reproductive healthcare services.

Insurance Coverage: Health insurance plans must provide coverage for a variety of dysmenorrhea treatments, particularly for severe cases associated with conditions such as endometriosis or fibroids, to reduce the financial burden on women seeking care.

7.1.2. Menstrual Health Education

Integration into School Programs: Governments and educational authorities should integrate menstrual health, including dysmenorrhea, into school health education. Comprehensive education programs can break down menstrual stigma and equip young women with knowledge on how to manage symptoms and seek medical help when needed.

Public Awareness Campaigns: National awareness initiatives can inform the public about the causes and treatments of dysmenorrhea, reducing stigma and encouraging affected women to seek healthcare solutions.

7.1.3. Workplace and Employment Rights

Menstrual Leave: Governments and organizations could introduce menstrual leave policies that allow women to take time off work without penalty when experiencing severe menstrual pain. This could minimize workplace discrimination and recognize the impact of dysmenorrhea on productivity and well-being.

Flexible Work Policies: Offering flexible work hours or remote work options to women with severe dysmenorrhea can foster a more inclusive work environment and reduce absenteeism.

Anti-Discrimination Regulations: Policies should be in place to protect women from workplace discrimination related to dysmenorrhea, ensuring they are not penalized for needing reasonable accommodations for pain management.

7.1.4. Research and Financial Support

Boosting Research Funding: Governments should increase financial support for research on dysmenorrhea, particularly for severe cases tied to conditions such as endometriosis or PCOS. This research could lead to better treatment options and a deeper understanding of the long-term effects on women's health.

Data Collection on Menstrual Health: Including menstrual health questions in national health surveys would provide valuable data on dysmenorrhea prevalence, aiding in more informed policy decisions and resource allocation.

7.1.5. Gender Equality and Social Justice

Reproductive Health Rights: Recognizing menstrual health, including the management of dysmenorrhea, as a fundamental reproductive right can prompt governments to ensure women have access to affordable and effective healthcare.

Addressing Stigma and Cultural Norms: Policymakers should work to eliminate menstrual stigma and cultural barriers by promoting gender-sensitive healthcare approaches and legal protections for women's health.

7.1.6. School Policies

Menstrual Health Support in Schools: Schools should implement policies that allow students to manage dysmenorrhea without academic penalties. Providing menstrual products and permitting flexible participation in physical activities can help prevent young girls from missing school due to menstrual pain.

7.1.7. Global Health and Development Goals

Linking to SDGs: Dysmenorrhea should be acknowledged as part of global health and development efforts, particularly in alignment with Sustainable Development Goal 3 (Good Health and Well-Being) and Goal 5 (Gender Equality). Addressing menstrual health can help reduce gender disparities and improve women's overall health and economic participation.

In conclusion, addressing dysmenorrhea through targeted policies is crucial for promoting gender equality, improving access to healthcare, and recognizing menstrual health as a public health priority. Effective policies can significantly reduce the burden of dysmenorrhea, benefiting both individual women and society as a whole.[44,45,46,47].

8.1 Reserch and future directions

Research into dysmenorrhea, or painful menstruation, is crucial for improving knowledge, treatment, and management of this prevalent but often underappreciated condition. The expanding research in this field focuses on both the underlying biological mechanisms and innovative treatment methods. These future research directions hold the potential to significantly enhance women's health outcomes and quality of life. Key research areas and emerging trends include:

8.1.1. Understanding Biological Mechanisms

Pathophysiology: Ongoing research aims to better understand the physiological and biological processes that trigger dysmenorrhea, including the role of prostaglandins, hormonal shifts, and inflammatory responses. Greater clarity on these mechanisms could result in more precise and effective treatment options.

Genetic and Epigenetic Contributions: Studies investigating genetic and epigenetic factors associated with dysmenorrhea may identify women who are more susceptible to the condition. This could lead to personalized approaches to treatment in the future.

8.1.2 Innovative Treatment Approaches

Non-Drug Therapies: Non-pharmacological treatments like acupuncture, transcutaneous electrical nerve stimulation (TENS), and physical therapy are gaining attention as alternatives to standard medications. Research is exploring how these treatments can be incorporated into mainstream care.

New Medications: Researchers are developing new drugs that more accurately target the specific pain mechanisms of dysmenorrhea. This includes novel anti-inflammatory agents, hormonal therapies, and pain management strategies with fewer side effects compared to current treatments like NSAIDs.

8.1.3 Connections to Other Health Conditions

Endometriosis and Gynecological Disorders: Dysmenorrhea is often associated with conditions such as endometriosis, adenomyosis, or fibroids. Research is working to improve diagnostic methods to distinguish between primary dysmenorrhea (unrelated to other conditions) and secondary dysmenorrhea caused by these disorders. Early and accurate diagnosis could lead to more targeted treatment.

PCOS and Hormonal Imbalances: Research is also focusing on the connections between dysmenorrhea and hormonal disorders like polycystic ovary syndrome (PCOS). Understanding these hormonal and metabolic interactions could improve clinical management of both conditions.

8.1.4 Mental and Emotional Health Impact

Psychosocial Effects: Increasingly, research is examining the mental health consequences of chronic menstrual pain, with evidence suggesting links to anxiety, depression, and reduced quality of life. Future studies could explore integrated treatment approaches that combine physical and mental health care.

Quality of Life: Ongoing research is looking at the social, educational, and professional impacts of dysmenorrhea, such as its influence on school attendance, work productivity, and overall well-being. Findings from this research may guide future policy changes to better support women managing menstrual pain.

8.1.5 Personalized and Preventive Medicine

Tailored Treatments: Future studies are expected to focus on personalized medicine, customizing treatment plans based on individual risk factors, genetic makeup, lifestyle, and associated health conditions. This could lead to more effective and safer management of dysmenorrhea.

Preventive Strategies: Increasing research is focused on prevention, exploring how lifestyle interventions such as diet, physical activity, and stress reduction can help minimize the severity and frequency of dysmenorrhea. Early interventions for adolescents could significantly reduce long-term effects.

8.1.6 Technological Developments

Wearable Devices: New technology like wearable devices that track menstrual cycles and pain levels is becoming a valuable resource for both research and symptom management. These devices collect real-time data that helps researchers gain a better understanding of the condition and allows women to better manage their symptoms.

Telemedicine and Digital Health: The rise of telemedicine offers new opportunities for managing dysmenorrhea, providing easier access to healthcare providers, particularly in underserved areas. Digital health platforms can offer personalized care plans and mental health support through apps and online services.

8.1.7 Public Health and Policy Research

Global Health Disparities: Future research needs to focus on the global prevalence of dysmenorrhea, particularly in low-income settings where healthcare access is limited. Understanding the socio-economic and cultural factors influencing menstrual health can help address disparities in diagnosis and treatment.

Policy and Workplace Studies: Research into how workplace policies, healthcare access, and menstrual health education impact women with dysmenorrhea could lead to policy improvements. Data-driven recommendations can help create better support systems and reduce the societal burden of menstrual pain.

8.1.8 Long-Term Health Implications

Chronic Pain Conditions: There is growing interest in the long-term health outcomes for women with dysmenorrhea, such as whether it increases the risk of developing other chronic pain disorders or reproductive health issues later in life. Research in this area could help identify at-risk individuals and improve preventive care.

Reproductive Health and Fertility: Future studies may explore potential links between dysmenorrhea and fertility issues, investigating how menstrual pain management affects reproductive health outcomes.[48,49,50].

Future research into dysmenorrhea promises to advance understanding of its causes, impacts, and treatment options. Progress in diagnostics, personalized care, and non-pharmacological treatments will open new avenues for enhancing the lives of women affected by this condition. Continued emphasis on public health initiatives and policy research will ensure that dysmenorrhea is recognized and treated as a critical women's health issue.

9.1 Recent advanced for treatment of dysmenorrhoea.

Recent advancements in dysmenorrhea treatment are broadening beyond traditional NSAIDs and hormone therapies. These new approaches target diverse aspects of pain physiology and emphasize a holistic approach to treatment. Below are some of these recent innovations:

9.1.1 Vitamin D Supplementation: Studies indicate that vitamin D can reduce inflammation and lower prostaglandin levels, both of which are connected to menstrual pain. Recent clinical trials have shown that vitamin D supplementation can help reduce pain levels, especially in primary dysmenorrhea, where pain is not caused by an underlying condition. Vitamin D likely reduces uterine muscle contractions by modulating inflammatory pathways.[51,52]

9.1.2 Nutraceuticals and Dietary Supplements: Nutraceuticals, which include active compounds like omega-3 fatty acids, curcumin, and magnesium, are increasingly used for pain management. These compounds offer anti-inflammatory and pain-relieving benefits that make them effective for menstrual pain. Omega-3s, for instance, can regulate prostaglandin levels—similar to NSAIDs—but without their gastrointestinal risks.[53,54]

9.1.3. Herbal Remedies: Traditional herbal formulas, such as Shaofu Zhuyu Decoction, are showing potential in relieving menstrual pain. These herbal remedies, common in Traditional Chinese Medicine (TCM), are being studied for their effects on blood flow, inflammation reduction, and uterine muscle relaxation. Research is now focusing on validating these natural treatments to integrate them with conventional care.[55,56]

9.1.4 Lifestyle and Psychological Interventions: Regular exercise, stretching, and yoga are known to boost circulation and decrease muscle tension, helping to alleviate menstrual cramps. Cognitive-behavioral therapy (CBT) is also being considered as a supportive therapy to help manage the psychological impact of chronic pain, often reducing the intensity of perceived pain and improving quality of life.[57,58]

9.1.5. Combination and Emerging Therapies: Current research is exploring combined treatments, such as pairing NSAIDs with vitamin D supplements, which may enable lower medication doses while effectively managing symptoms. This approach aims to maintain effective pain relief while reducing potential side effects, offering a more sustainable option for long-term care.[59]

These strategies reflect a comprehensive approach to dysmenorrhea, addressing both physical and psychological dimensions of pain. By tailoring treatments to individual needs and targeting diverse pain pathways, these innovations offer a more personalized, effective way to manage dysmenorrhea.[60]

CONCLUSION

In Expanding knowledge of its biological mechanisms, investigating new treatment methods, and addressing its wider impacts on mental health, reproductive health, and overall quality of life could lead to more effective and tailored interventions. Furthermore, personalized healthcare, technological innovations, and public health efforts will be key in developing comprehensive and inclusive care strategies. Elevating dysmenorrhea as a public health concern is crucial for improving women's health and advancing gender equity in healthcare systems.

REFERENCES

- [1]. McKenna KA, Fogleman CD. Dysmenorrhea. American family physician. 2021 Aug;104(2):164-70.
- [2]. Zondervan KT, Yudkin PL, Vessey MP, et al. The prevalence of chronic pelvic pain in the United Kingdom: a systematic review. Br J Obstet Gynaecol 1998;105:93–99. [DOI] [PubMed] [Google Scholar]
- [3]. Harlow SD, Campbell OM. Epidemiology of menstrual disorders in developing countries: a systematic review. BJOG 2004;111:6–16. [DOI] [PubMed] [Google Scholar]
- [4]. Latthe P, Latthe M, Gulmezoglu M, et al. WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. BMC Public Health 2006;6:177. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [5]. Latthe P, Mignini L, Gray R, et al. Factors predisposing women to chronic pelvic pain: systematic review. BMJ 2006;332:749–755. [DOI] [PMC free article] [PubMed] [Google Scholar]

- [6]. Sundell G, Milsom I, Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. *Br J Obstet Gynaecol* 1990;97:588–594. [DOI] [PubMed] [Google Scholar]
- [7]. Marjoribanks J, Proctor ML, Farquhar C. Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea. In: *The Cochrane Library*, Issue 4, 2009. Chichester, UK: John Wiley & Sons, Ltd. Search date 2003. [DOI] [PubMed] [Google Scholar]
- [8]. Mehlich DR, Ardia A, Pallotta T. Analgesia with ibuprofen arginate versus conventional ibuprofen for patients with dysmenorrhea: a crossover trial. *Curr Ther Res* 2003;64:327–337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [9]. Malmstrom K, Kotey P, Cichanowitz N, et al. Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial. *Gynecol Obstet Invest* 2003;56:65–69. [DOI] [PubMed] [Google Scholar]
- [10]. Daniels S, Gitton X, Zhou W, et al. Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials. *J Womens Health (Larchmt)* 2008;17:423–437. [DOI] [PubMed] [Google Scholar] (1981)
- [11]. R Itani, L Soubra, S Karout, D Rahme, L Karout and HMJ Khojah. Primary dysmenorrhea: Pathophysiology, diagnosis, and treatment updates. *Korean J. Fam. Med.* 2022; 43, 101-8.
- [12]. CA Enakpene, M Dalloul, C Petherkin-Caldwell, J Anopa and O Muneyyirci-Delale. Dysmenorrhea as a risk factor for Hyperemesis gravidarum. *J. Clin. Gynecol. Obstet.* 2015; 4, 283-9.
- [13]. Y Cheng, Y Chu, X Su, K Zhang, Y Zhang, Z Wang, W Xiao, L Zhao and X Chen. Pharmacokinetic - pharmacodynamic modeling to study the anti-dysmenorrhea effect of Guizhi Fuling capsule on primary dysmenorrhea rats. *Phytomedicine* 2018; 48, 141-51.
- [14]. Y Wei, T Ma, H Wang, J Xing, Y Wang, Z Gu, D Mu, Q Yin, X Cheng and C Wang. Extracts of compound Muniziqi granule suppressed uterus contraction and ameliorated oxytocin-induced primary dysmenorrhea. *J. Ethnopharmacol.* 2018; 223, 33-40.
- [15]. TC de Lima Araújo, PMN Menezes, TF Ribeiro, CAF Macêdo, NAC de Souza, KSB Lima, HF de Figueredo, FS Silva and LA Rolim. Cannabis sativa L. roots from northeast Brazil reduce abdominal contortions in a mouse model of primary dysmenorrhea. *J. Ethnopharmacol.* 2024; 318, 116891.
- [17]. M Tadese, A Kassa, AA Mulneh and G Altaye. Prevalence of dysmenorrhoea, associated risk factors and its relationship with academic performance among graduating female university students in Ethiopia: A cross-sectional study. *BMJ Open* 2021; 11, e043814.
- [18]. RA Lobo, DM Gershenson, GM Lentz and FA Valea. *Comprehensive gynecology e-book*. 7th ed. Elsevier Health Sciences, Philadelphia, 2016.
- [19]. DC Dutta, H Konar and DC Dutta. *Textbook of gynecology: Including contraception*. Jaypee Brothers Medical Publishers, New Delhi, India, 2013.
- [20]. E Fernández-Martínez, MD Onieva-Zafra and ML Parra-Fernández. The impact of dysmenorrhea on quality of life among Spanish female university students. *Int. J. Environ. Res. Publ. Health* 2019; 16, 713.
- [21]. SA Ryan. The treatment of dysmenorrhea. *Pediatr. Clin. North Am.* 2017; 64, 331-42.
- [22]. CF Draper, K Duisters, B Weger, A Chakrabarti, AC Harms, L Brennan, T Hankemeier, L Goulet, T Konz, FP Martin, S Moco and JVD Greef. Menstrual cycle rhythmicity: Metabolic patterns in healthy women. *Sci. Rep.* 2018; 8, 14568.
- [23]. Z Barcikowska, E Rajkowska-Labon, ME Grzybowska, R Hansdorfer-Korzon and K Zorena. Inflammatory markers in dysmenorrhea and therapeutic options. *Int. J. Environ. Res. Publ. Health* 2020; 17, 1191.
- [24]. KA Kho and JK Shields. Diagnosis and management of primary dysmenorrhea. *JAMA* 2020; 323, 268-9.
- [25]. N Muhammad, M Saeed and H Khan. Antipyretic, analgesic and anti-inflammatory activity of *Viola betonicifolia* whole plant. *BMC Complementary Altern. Med.* 2012; 12, 59.
- [26]. MW Ha and SM Paek. Recent advances in the synthesis of ibuprofen and naproxen. *Molecules* 2021; 26, 4792.
- [27]. Armour M, Ferfolja T, Curry C, Hyman MS, Parry K, Chalmers KJ, et al. The prevalence and educational impact of pelvic and menstrual pain in Australia: a national online survey of 4202 young women aged 13–25 years. *J Pediatr Adolesc Gynecol.* (2020) 33(5):511–8. doi: 10.1016/j.jpag.2020.06.007
- [28]. De Sanctis V, Soliman A, Bernasconi S, Bianchin L, Bona G, Bozzola M, et al. Primary dysmenorrhea in adolescents: prevalence, impact and recent knowledge. *Pediatr Endocrinol Rev.* (2015) 13(2):512–20. PMID: 26841639.26841639
- [29]. Dixon S, McNiven A, Talbot A, Hinton L. Navigating possible endometriosis in primary care: a qualitative study of GP perspectives. *Br J Gen Pract.* (2021) 71(710):e668–e76. doi: 10.3399/BJGP.2021.0030
- [30]. Mama S. T., Advances in the management of endometriosis in the adolescent, *Current Opinion in Obstetrics & Gynecology.* (2018) 30, no. 5, 326–330, <https://doi.org/10.1097/gco.0000000000000483>, 2-s2.0-85056547900.
- [31]. Payne J. A., Acupuncture for endometriosis: a case study, *Medical Acupuncture.* (2019) 31, no. 6, 392–394, <https://doi.org/10.1089/acu.2019.1379>.
- [32]. Eisenberg V., Weil C., Chodick G., and Shalev V., Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members, *BJOG: An International Journal of Obstetrics & Gynaecology.* (2017) 125, no. 1, 55–62, <https://doi.org/10.1111/1471-0528.14711>, 2-s2.0-85020757935.
- [33]. 4 Coxon L., Horne A. W., and Vincent K., Pathophysiology of endometriosis-associated pain: a review of pelvic and central nervous system mechanisms, *Best Practice & Research Clinical Obstetrics & Gynaecology.* (2018) 51, 53–67, <https://doi.org/10.1016/j.bpobgyn.2018.01.014>, 2-s2.0-85042907617.
- [34]. Morotti M., Vincent K., and Becker C. M., Mechanisms of pain in endometriosis, *European Journal of Obstetrics & Gynecology and Reproductive Biology.* (2017) 209, 8–13, <https://doi.org/10.1016/j.ejogrb.2016.07.497>, 2-s2.0-84994559769.
- [35]. Su W. L., Ma L. L., Zhang X. H. et al., Research progress of pain mechanism related to endometriosis, *Concord Medical Journal.* (2020) 11, no. 4, 439–442.
- [36]. Chen W., Li E.-c., and Zheng W.-r., Policies on Chinese medicine in China may have enlightenments to complementary and alternative medicine in the world, *Chinese Journal of Integrative Medicine.* (2018) 24, no. 10, 789–793, <https://doi.org/10.1007/s11655-018-3008-0>, 2-s2.0-85049140207.
- [37]. Chen Y. S., Zhu G. H., Dong J. X. et al., The effect of Shaofu Zhuyu decoction on the proliferation, apoptosis and angiogenesis of the eutopic endometrium in rats with endometriosis, *Journal of Southeast University (Medical Edition).* (2017) 36, no. 2, 142–148.
- [38]. E.M. Lichten et al. Surgical treatment of primary dysmenorrhea with laparoscopic uterine nerve ablation *Reprod Med* (1987).
- [39]. G. Eryilmaz et al. Evaluation of menstrual pain management approaches by Northeastern Anatolian Adolescents *Pain Manag Nurs* (2009).
- [40]. Aberger EW, Denney DR, Hutchings DF. Pain sensitivity and coping strategies among dysmenorrheic women: much ado about nothing. *Behav Res Ther* 1983;21:119–127.
- [41]. Akerlund M. Pathophysiology of dysmenorrhea. *Acta Obstet Gynecol Scand Suppl* 1979;87:27–32.

- [42]. Akerlund M. Vasopressin and oxytocin in normal reproduction and in the pathophysiology of preterm labour and primary dysmenorrhoea. Development of receptor antagonists for therapeutic use in these conditions. *Rocz Akad Med Bialymst* 2004;49:18–21.
- [43]. Akin M, Price W, Rodriguez GJr, Erasala G, Hurley G, Smith RP. Continuous, low-level, topical heat wrap therapy as compared to acetaminophen for primary dysmenorrhea. *J Reprod Med* 2004;49:739–745.
- [44]. Altunyurt S, Gol M, Altunyurt S, Sezer O, Demir N. Primary dysmenorrhea and uterine blood flow: a color Doppler study. *J Reprod Med* 2005;50:251–255.
- [45]. Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. *Am J Obstet Gynecol* 1982;144:655–660.
- [46]. Araujo P, Hachul H, Santos-Silva R, Bittencourt LR, Tufik S, Andersen ML. Sleep pattern in women with menstrual pain. *Sleep Med* 2011;12:1028–1030.
- [47]. Ayan M, Sogut E, Tas U, Erdemir F, Sahin M, Suren M, Kaya Z, Demirturk F. Pain levels associated with renal colic and primary dysmenorrhea: a prospective controlled study with objective and subjective outcomes. *Arch Gynecol Obstet* 2012;286:403–409.
- [48]. Baker FC, Driver HS, Rogers GG, Paiker J, Mitchell D. High nocturnal body temperatures and disturbed sleep in women with primary dysmenorrhea. *Am J Physiol* 1999;277:E1013–E1021.
- [49]. Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. *J Rheumatol* 1995;22:639–643.
- [50]. Bianchi M. Are all NSAIDs other than 'coxibs' really equal? *Trends Pharmacol Sci* 2004;25:6–7.
- [51]. Blankstein U, Chen J, Diamant NE, Davis KD. Altered brain structure in irritable bowel syndrome: potential contributions of pre-existing and disease-driven factors. *Gastroenterol* 2010;138:1783–1789.
- [52]. Brumovsky PR, Gebhart GF. Visceral organ cross-sensitization—an integrated perspective. *Auton Neurosci* 2010;153:106–115.
- [53]. Campbell MA, McGrath PJ. Non-pharmacologic strategies used by adolescents for the management of menstrual discomfort. *Clin J Pain* 1999;15:313–320.
- [54]. Chan WY, Dawood MY. Prostaglandin levels in menstrual fluid of nondysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or ibuprofen therapy. *Adv Prostaglandin Thromboxane Res* 1980;8:1443–1447.
- [55]. Chantler I, Mitchell D, Fuller A. The effects of three cyclo-oxygenase inhibitors with different cyclo-oxygenase-2 specificity on intensity of primary dysmenorrhoeic pain. *Clin J Pain* 2008;24:39–44.
- [56]. McKenna KA, Fogleman CD. Dysmenorrhea. *American family physician*. 2021 Aug;104(2):164-70.
- [57]. Parker MA, Sneddon AE, Arbon P. The menstrual disorder of teenagers (MDOT) study: Determining typical menstrual patterns and menstrual disturbance in a large population-based study of Australian teenagers. *BJOG* 2010;117:185–192.
- [58]. Wilson CA, Keyes WR Jr. A survey of adolescent dysmenorrhea and premenstrual symptom frequency. A model program for prevention, detection, and treatment. *J Adolesc Health Care* 1989;10:317–322.
- [59]. French L. Dysmenorrhea in adolescents: Diagnosis and treatment. *Paediatr Drugs* 2008;10:1–7.